Synosia Will Initiate Phase II Studies Of Rufinamide In Anxiety, Bipolar Disorders In March
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will evaluate 500 mg and 1 gm doses of the drug, after assessing three different doses in a proof-of-concept study.
You may also be interested in...
Eisai Rufinamide Study Reports 33 Percent Reduction In Epileptic Seizures
Drug is "approvable" for Lennox-Gastaut syndrome, partial onset seizures since 2006.
Eisai Rufinamide Study Reports 33 Percent Reduction In Epileptic Seizures
Drug is "approvable" for Lennox-Gastaut syndrome, partial onset seizures since 2006.
Synosia Licenses Rufinamide From Novartis In Anxiety, Bipolar Indications
The sodium channel blocker could have advantages over selective serotonin reuptake inhibitors, CEO tells “The Pink Sheet” DAILY.